Last C$0.60 CAD
Change Today -0.04 / -6.25%
Volume 519.6K
EDT On Other Exchanges
Symbol
Exchange
OTC US
Berlin
Toronto
As of 3:59 PM 03/3/15 All times are local (Market data is delayed by at least 15 minutes).

spectral medical inc (EDT) Snapshot

Open
C$0.63
Previous Close
C$0.64
Day High
C$0.64
Day Low
C$0.58
52 Week High
03/2/15 - C$0.64
52 Week Low
03/19/14 - C$0.22
Market Cap
107.8M
Average Volume 10 Days
386.8K
EPS TTM
C$-0.08
Shares Outstanding
179.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SPECTRAL MEDICAL INC (EDT)

Related News

No related news articles were found.

spectral medical inc (EDT) Related Businessweek News

No Related Businessweek News Found

spectral medical inc (EDT) Details

Spectral Medical Inc. develops and commercializes theranostic treatment for severe sepsis in North America. The company’s products include Endotoxin Activity Assay, a rapid diagnostic test for detection of components of gram negative bacterial cell wall; and Toraymyxin, a therapeutic hemoperfusion device for the treatment of sepsis that removes endotoxin from the bloodstream. It is also involved in the development, production, and marketing of recombinant cardiac proteins, antibodies, and calibrators for use in research and development, as well as in products manufactured by other diagnostic companies. The company was formerly known as Spectral Diagnostics Inc. and changed its name to Spectral Medical Inc. in December 2014. Spectral Medical Inc. was founded in 1991 and is headquartered in Toronto, Canada.

20 Employees
Last Reported Date: 03/27/14
Founded in 1991

spectral medical inc (EDT) Top Compensated Officers

Chief Executive Officer, President, Director ...
Total Annual Compensation: C$424.9K
Chief Financial Officer, Executive Vice Presi...
Total Annual Compensation: C$265.6K
Vice President of Clinical Development
Total Annual Compensation: C$201.8K
Vice President of Sales and Marketing
Total Annual Compensation: C$117.8K
Compensation as of Fiscal Year 2013.

spectral medical inc (EDT) Key Developments

Spectral on Track for Potential Commercialization in First Half of 2016

Spectral Medical Inc. announced continuing progress towards commercialization of a medical device that addresses the critical care needs of patients in a $3 billion market. Spectral’s septic shock treatment is the only medical device currently in an active U.S. Food and Drug Administration (the “FDA”) approved Phase III clinical trial to address this deadly condition which has a mortality rate in excess of forty percent. The product has been in use in Japan and Europe, with published study results and data from medical registries showing success in significantly reducing mortality rates caused by septic shock and demonstrating that the most severely ill patients benefit most from a two column treatment protocol. The company’s EUPHRATES trial targets the same severely ill patient population with a similar treatment protocol. Over 100,000 patients have now been treated with this medical device outside of North America.

Spectral Diagnostics Inc. will Change its Name to Spectral Medical Inc

Effective December 31, 2014, Spectral Diagnostics Inc. will change its name to Spectral Medical Inc.

Spectral Diagnostics Inc. will Change its Ticker to EDT from SDI

Effective December 31, 2014, Spectral Diagnostics Inc. will change its The Toronto Stock Exchange stock ticker symbol to EDT from SDI.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
EDT:CN C$0.60 CAD -0.04

EDT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for EDT.
View Industry Companies
 

Industry Analysis

EDT

Industry Average

Valuation EDT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 31.5x
Price/Book 8.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 29.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SPECTRAL MEDICAL INC, please visit www.spectraldx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.